HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.

Abstract
The tumor-associated vasculature imposes major structural and biochemical barriers to the infiltration of effector T cells and effective tumor control. Correlations between stimulator of interferon genes (STING) pathway activation and spontaneous T cell infiltration in human cancers led us to evaluate the effect of STING-activating nanoparticles (STANs), which are a polymersome-based platform for the delivery of a cyclic dinucleotide STING agonist, on the tumor vasculature and attendant effects on T cell infiltration and antitumor function. In multiple mouse tumor models, intravenous administration of STANs promoted vascular normalization, evidenced by improved vascular integrity, reduced tumor hypoxia, and increased endothelial cell expression of T cell adhesion molecules. STAN-mediated vascular reprogramming enhanced the infiltration, proliferation, and function of antitumor T cells and potentiated the response to immune checkpoint inhibitors and adoptive T cell therapy. We present STANs as a multimodal platform that activates and normalizes the tumor microenvironment to enhance T cell infiltration and function and augments responses to immunotherapy.
AuthorsLihong Wang-Bishop, Blaise R Kimmel, Verra M Ngwa, Matthew Z Madden, Jessalyn J Baljon, David C Florian, Ann Hanna, Lucinda E Pastora, Taylor L Sheehy, Alexander J Kwiatkowski, Mohamed Wehbe, Xiaona Wen, Kyle W Becker, Kyle M Garland, Jacob A Schulman, Daniel Shae, Deanna Edwards, Melissa M Wolf, Rossane Delapp, Plamen P Christov, Kathryn E Beckermann, Justin M Balko, W Kimryn Rathmell, Jeffrey C Rathmell, Jin Chen, John T Wilson
JournalScience immunology (Sci Immunol) Vol. 8 Issue 83 Pg. eadd1153 (05 12 2023) ISSN: 2470-9468 [Electronic] United States
PMID37146128 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Topics
  • Mice
  • Animals
  • Humans
  • Neoplasms
  • Immunotherapy
  • T-Lymphocytes
  • Nanoparticles
  • Disease Models, Animal
  • Tumor Microenvironment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: